Various immune mechanisms have been reported to contribute to the progressive destruction of Th cells in HIV-1i-infected patients. Among these, complement mediated lysis of infected cells has been suggested. An increased sensitivity of lymphocytes from HIV-1-infected patients to lysis by monoclonal antibodies directed to MHC class I antigen and complement has been directly correlated with a decreased expression of the decay accelerating factor (CD55). It also has been reported that the expression of the membrane inhibitor of reactive lysis (CD59) is decreased during HIV-1 infection. We examined the effect of antibodies in the serum of HIV-1-positive individuals and normal human serum (NHS) as source of complement on several HIV-1-infected cell lines differing in their expression of CD55 and CD59.
Introduction
Various immune mechanisms have been reported to contribute to the progressive destruction of Th cells in HIV-1i-infected patients. Among these, complement mediated lysis of infected cells has been suggested. An increased sensitivity of lymphocytes from HIV-1-infected patients to lysis by monoclonal antibodies directed to MHC class I antigen and complement has been directly correlated with a decreased expression of the decay accelerating factor (CD55). It also has been reported that the expression of the membrane inhibitor of reactive lysis (CD59) is decreased during HIV-1 infection. We examined the effect of antibodies in the serum of HIV-1-positive individuals and normal human serum (NHS) as source of complement on several HIV-1-infected cell lines differing in their expression of CD55 and CD59.
When HIV-1-infected target cells without membrane expression of CD55 and CD59 were used, a highly significant cytotoxic effect was observed in the presence of heat inactivated anti-HIV-1-positive sera and NHS, while heat-inactivated anti-HIV-1-negative sera and NHS were unable to induce cytolysis. Similar results were obtained using purified IgG isolated from HIV-1-positive sera and either NHS or guinea pig serum as source of complement. Lysis of HIV-1-infected cells correlated with expression of viral antigens on the cell surface. HIV-1-infected CD55 and CD59 positive target cells showed specific lysis, when the function of these molecules was abrogated by blocking antibodies to CD55 and CD59. The finding of anti-HIV-1-specific cytotoxic antibodies in sera from HIV-1-infected patients should be considered in the pathogenesis of the HIV-1 infection. (J. Clin Infection of CD4+ lymphocytes and monocytoid cells with HIV-1 is one of the most significant findings in AIDS (1) . Although neutralizing antibodies directed to the major viral glycoproteins have been described in infected individuals (2) , the role of anti-HIV-1 antibodies in the pathogenesis of AIDS is still subject of discussion (3) . In addition to neutralizing antibodies, antibody-dependent cellular cytotoxicity against virus-infected cells has been suggested as a potential inhibitor of viral spread (4) (5) (6) (7) .
A number of studies on the interaction between human complement and viruses have been performed. Whereas Oncornaviruses (8) and RNA tumor viruses (9, 10) activate complement and undergo lysis, inactivation or lysis of HIV-1 by normal human serum (NHS)' has not been observed (11) although complement activation does occur in the absence of anti-HIV-1 antibodies (12) (13) (14) (15) . HIV-1 appears to activate the classical pathway directly (16) and recent data demonstrating complement activation as a result of binding of Clq to gpl6O support this finding ( 17 ). In contrast, increased neutralization of virions has been described when HIV-1-specific antibodies and complement are used. In this reaction, antibodies to the V3 loop of the gpl2O of HIV-1 are particularly effective in inducing complement activation and lysis of the virions (18) .
In addition to complement activation by virions, virus-infected cells might also activate complement (19) (20) (21) . Activation of the classical pathway has been demonstrated using cells coinfected with HIV-1 and HTLV-1 but not with cells infected with HIV-1 alone (22, 23) . Lysis of HIV-1-infected U937 or KE37 cells has been observed with some sera from HIV-1-infected individuals (24, 25) . Sera from HIV-1-infected chimpanzees and goats immunized with gp120 also contained cytolytic activity (26) . In contrast, several groups have been unable to demonstrate lysis of HIV-1-infected human cell lines using anti-HIV-1 positive sera from infected individuals and human complement (5, 7, 26) .
Normal host cells are protected from the lytic action of homologous complement by membrane proteins that strictly regulate the activation and deposition of complement proteins. The membrane proteins complement receptor 1 (CR1 or CD35) (27), membrane cofactor protein (MCP or CD46) (28) , and decay accelerating factor (DAF or CD55) (29) , induce the dissociation of the C3 convertases, thus preventing further activation of complement. In addition CD35 and CD46 act as cofactors for C3b cleavage by the serum enzyme factor I (27, 28).
The membrane inhibitor of reactive lysis (MIRL or CD59) (30) (31) (32) and homologous restriction factor (HRF) (33) are two membrane proteins that prevent the assembly of the membrane attack complex (C5b-9). A decreased expression of CD55 and CD59 has been demonstrated on the membrane of lymphocytes of HIV-1 -infected patients (34, 35) . This observation appears to be related to the increased sensitivity of lymphocytes from these patients to the lytic action of complement when cells were sensitized with anti-MHC class I monoclonal antibody (34) .
Using several T-cell lines that differ in the expression of the complement regulatory proteins, CD55 and CD59, we have undertaken an evaluation of the role of these proteins in the lysis of HIV-1 -infected cells sensitized with serum from HIV-1 -infected subjects.
Methods
Cells and viruses. The HIV-1 virus strain HTLV-IllB was replicated in the human permanent cell lines H9, KE37 (H9 subclone), U937, Molt-4 and CEM. The uninfected and HIV-1-infected cells were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated FCS, 100 U/ml penicillin, and 100 ,ug/ml streptomycin (all from Gibco, Eggenstein, Germany). Cells were kept in culture for eight weeks after infection and they were propagated twice weekly. All antibodies mentioned above were used for immunofluorescence staining at a dilution of 1:100. Anti-mouse-FITC ( 1:30) and anti-human-FITC, F(ab')2 fragments (1:30) were purchased from Dianova. As control for the indirect immunofluorescence an isotypic mouse IgG antibody was purchased from Becton Dickinson.
For blocking experiments, BRIC 229 (CD59) was purchased from IBGRL (Bristol, Great Britain). It has previously been published that the antibody BRIC 229 does not fix complement (38) . An antiserum to CD55 was obtained from rabbits immunized with DAF purified from human erythrocytes (39) . F(ab')2-fragments were prepared by established procedures (40) .
Immunofluorescence staining. The expression of HIV-1 proteins in the various cell lines was monitored by routine immunofluorescence microscopy using a high titer human anti-HIV-1 serum and FITC antihuman immunoglobulins at a dilution of 1:30 as reported previously (41). Discrimination between total and membrane expression of viral antigens was accomplished by staining the cells either unfixed or after permeabilization of the cell membrane with acetone/methanol. FACS analysis. Flow cytometric measurements on stained H9, KE37, U937, Molt-4, and CEM cells were performed using a FACScan (Becton Dickinson) equipped with an argon ion laser running at an extinction line of 488 nm. Logarithmic amplification of fluorescence signals was used. Based on forward light scatter, 10,000 triggered events were counted, and the data were analyzed with the FACScan Lysis II Software Version (Becton Dickinson).
Antibody-dependent complement-mediated cytotoxicity. Cytotoxicity was measured using the 51Cr-release assay (22) , 108 HIV-1-infected or uninfected H9, KE37, U937, Molt-4 or CEM cells (I07 cells per ml)
were labeled with 100 ,uCi of sodium chromate (5"Cr) ( and the radioactivity in 50 ,l of supernatants was measured in a gamma counter. All experiments were carried out in triplicates. Negative controls included culture medium alone and samples without complement. To measure maximum 51Cr-release, a sample of labeled cells was lysed with 200 j1 Triton X-100 (5% PBS). In some experiments antibodydependent complement-mediated cytotoxicity was also analyzed by propidium iodide (PI) uptake using flow cytometry. PI was prepared by dissolving 0.05 mg in 100 ml PBS (PI-PBS) as described elsewhere (42) . One million cells in 50 td RPMI 1640/10% FCS were mixed in Eppendorf tubes with equal volumes of anti-HIV-1-positive serum or controls and NHS as described above. After incubation cells were washed, resuspended in 1 ml of PI-PBS and kept for Fig. 1 ). CD35 was not expressed on H9, KE37, and U937 cells (Table I ).
All cell lines tested were susceptible to HIV-1 infection, but virus production was delayed in U937 cells (Table I) . We attribute this phenomenon to the diminished expression of CD4 molecules (Table I) To examine human sera from HIV-1-infected individuals for the presence of antibodies capable of mediating cytotoxicity, 50 HIV-1 antibody-positive human sera and 50 negative control sera were tested using KE37 cells infected with the HTLV-IIIB isolate of HIV-1. All sera containing antibodies to HIV-1 -mediated cytotoxicity in the presence of NHS used as complement source. When KE37 cells with maximum expression of viral antigens on their surface were used as target cells, the specific 51Cr-release ranged from 15% to 58% with a mean release of 36% (±9%) (Figs. 2 B and 3) . The 50 HIV-1-negative control sera showed a 51Cr release of 1.8% (±0.7%). The difference between positive and negative sera was highly significant (Wilcoxon Signed Rank P < 0.001). Medium alone and NHS controls showed a background spontaneous lysis of 3.5 and 3.7%, respectively. Maximal lysis of infected cells was observed between days 7 and 28 after infection, when expression of viral antigens on the cell surface reached peak values (Fig. 2, A and B) . Cytotoxic activity dropped to nonsignificant values with decreased expression of viral antigens on the cell membrane although intracellular expression remained at high levels for several weeks after infection (> 40% of cells positive by immunofluorescent staining) (Fig. 2, A and B) . These experiments demonstrate that the cytolytic activity in serum of HIV-1-infected individuals in the presence of complement is dependent on the expression of viral antigens on the cell membrane.
FACS analysis of PI-stained cells was also used to assess cytotoxicity (Fig. 4) . When compared to 5"Cr-release, PI uptake yielded somewhat lower values with a mean value of 28% (±7%) and individual lysis ranging from 10 to 52% (Fig. 3) . This lower value measured by FACS analysis may be due to disruption of cellular membranes and desintegration of DNA resulting in a reduced PI staining. Similar PI uptake with a mean lysis 27% (±6%) was obtained when the IgG fractions of 10 HIV-l-positive sera were analyzed (Fig. 3) . and albumin containing fractions, as well as all fractions from HIV-l-negative sera did not cause significant PI uptake. The utilization of the classical pathway of complement by anti-HIV-1 antibodies was documented by abrogation of the cytotoxic effect upon addition of MgEGTA to the NHS. 12 anti-HIV-1-positive sera causing high PI uptake with NHS as source of complement (mean lysis 32% [±7%]) did no longer show cytolytic activity (< 5%) when MgEGTA was added (Fig. 3) . Guinea pig serum diluted 1:10 used as a source of heterologous complement produced similar PI uptake to NHS (mean PI uptake of 31% [±5%]), while HIV-1-negative sera produced no significant lysis (< 3%).
Cytotoxicity was dependent on the concentration of antibody and complement used. Five sera from HIV-1-infected individuals were used in dilution experiments. A representative experiment is shown in Fig. 5 . The HIV-l-positive sera used as a source of antibodies could be diluted 1:64. A dilution of 1:16 of complement source drastically reduced cytotoxic activity. When HIV-1-infected H9 (Fig. 6 ), Molt-4 and CEM cells (data not shown) expressing CD55 and CD59 were used as targets for antibody-dependent complement-mediated cytotoxicity, no significant lysis was observed compared with negative controls suggesting that the absence of the regulatory proteins CD55 and CD59 allow the KE37 cells to undergo lysis in the presence of sera of HIV-l -infected individuals.
Functional effect ofblocking CD55 and CDS9 using specific antibodies. To clarify the role of CD55 and CD59 in regulation of the lysis of HIV-l-infected cells by serum of HIV-l-infected individuals and complement, H9, Molt-4, and CEM cells that express these regulatory proteins were incubated with anti-CD55 or F(ab')2-fragments, or anti-CD59 blocking antibodies. After incubation, as shown in Fig. 6 and 7 (data not shown for Molt-4 and CEM cells), the cells were rendered susceptible to lysis by anti-HIV-1 sera and NHS (mean specific lysis 26% [ ±5% ] ). Similar results were obtained when guinea pig serum was used as source of complement (data not shown). Increasing concentrations of blocking antibodies to CD55 and CD59 showed enhanced lysis in a dose response fashion; the combination of both antibodies led to an increased cytolysis as compared to each antibody alone. Fig. 7 demonstrates a typical dose response histogram of a representative experiment. Antibodies to anti-CD4, another surface determinant without complement regulatory function, did not lead to specific lysis of HIV-1 -infected or uninfected H9 or KE37 cells using NHS as complement source (data not shown). Neither anti-CD55 nor anti-CD59 antibodies used in these experiments mediated specific lysis in the presence of human (Fig. 6 ) or guinea pig complement in the absence of anti-HIV-1 sera. No specific lysis was detected after incubation of HIV-1 -infected H9 cells with anti-HIV-1 positive sera and NHS (Fig. 6) (27) . CD59 binds C8 and C9, successfully preventing C9 polymerization and insertion into the cell membrane (32, 43) . Lysis of cells bearing CD59 is down regulated when cells and complement are homologous with regard to species, but not when a heterologous source of complement is used (31) . The significance of these regulatory proteins on the lytic events induced by anti-HIV-1 antibodies in sera from infected individuals and human complement was demonstrated in our experiments using HIV-l-infected T cells of the line KE37 as targets for antibody-dependent complement-mediated cytotoxicity. These cells do not express CD55 and CD59 on their membranes. All sera from HIV-1-infected patients exhibited cytotoxic activity, while sera from noninfected individuals did not. H9 cells, Molt-4 and CEM that express CD55 and CD59 were resistant to lysis by HIV-1 -positive sera and complement. Only by using blocking antibodies to CD55 and CD59, which did not show complement activation, a dose dependent enhancement of antibody-dependent complement-mediated cytotoxicity could be observed. Thus, lysis of HIV-l-infected cells by anti-HIV-1 antibodies and complement is a highly specific and sensitive indicator of HIV-1 infection when the infected target cells lack CD55 and CD59.
Using anti-MHC class I antibodies and complement an enhanced complement sensitivity of lymphocytes from patients with HIV-1 infection has been shown to be related to a diminished expression of CD55 (34) and CD59 on these cells. Incorporation of exogenous CD55 into the lymphocyte membrane ameliorated their abnormal sensitivity to complement (35 (46) . It has been reported that isolated gpl20 bound to CD4 on normal lymphocytes may serve as target for antibody dependent cytotoxic attack (5) . Antibodies to the V3 region of gpl2O are particularly effective in inducing complement activation by HIV-1 (22) . Recently, direct activation of complement by rgpl2O has been described. This activation, however, did not result in lysis of rgpl20-coated CD4' cells (47) . Preliminary experiments in our laboratory indicate that some of the patient sera tested (3/15) contain cytotoxic antibodies that recognize the HTLV-IIIB gpl2O and lyse noninfected KE37 cells preincubated with recombinant soluble gpl2O (data not shown). In agreement with reported findings (22) , our results suggest that epitopes in the hypervariable regions of gpl20 might serve as targets for antibody-dependent complement-mediated cytotoxicity. Such restricted antigenic recognition may explain why only a few sera were able to react with the relevant epitopes of HTLV-I1B gpl20, while almost all sera tested were cytotoxic when HTLV-IIIB-infected KE37 cells were used as targets. These findings suggest that besides gpl20 additional antigenic sites are recognized by the antibodies in HIV-l-positive serum to produce lysis of infected cells in the presence of complement (25) .
Lysis of HIV-l-infected KE37 cells by HIV-1 sera in the presence of complement occurred regardless of the clinical status of the patient, the absolute number of CD4+ cells or the CD4/CD8 ratio in peripheral blood. The lytic mechanisms leading to the continuous loss of CD4+ lymphocytes in vivo over a period of several years may require both a continuous presence of cytotoxic antibodies and a decreased expression of complement regulatory factors.
In conclusion, we have established an experimental model to investigate the effect ofcytotoxic antibodies and complement in the course of HIV-1 infection. We detected cytotoxic antibodies against HIV-1-positive cells in all sera from HIV-1-infected individuals. The observation that CD55 and CD59 protect target cells from the lytic action of HIV-1 antibodies and complement explains the contradictory results of other investigators depending on the cell lines used (5, (24) (25) (26) . The complement mediated cytotoxicity of anti-HIV-l antibodies may contribute to the progressive loss of CD4+ lymphocytes. Further studies on different T cell subsets obtained from HIV-l-infected patients are required to provide evidence for the in vivo significance of our findings.
